NEW ISSUE
LM revascularisation, annulus rupture, risk stratification, renal denervation
May 20, 2020
1. Yale University School of Medicine, New Haven, CT, USA; 2. Barts Heart Centre, London and Queen Mary University of London, London, United Kingdom; 3. Department of Cardiology, Maria Cecilia Hospital - GVM Care & Research, Cotignola, Italy; 4. Clinical and Experimental Interventional Cardiology, University of Saarland, Homburg/Saar, Germany; 5. Department of Medical Science, Cardiology, Uppsala University, Uppsala, Sweden; 6. Interventional Cardiology, Clinique Pasteur, Toulouse, France; 7. Maria Cecilia Hospital, Cotignola, Italy; 8. Cardiology and Cardiovascular Department, Humanitas Gavazzeni Hospital, Bergamo, Italy; 9. Department of Vascular Surgery, AZ Sint Blasius, Dendermonde, Belgium; 10. Foundation for Cardiovascular Research and Education, Münster, Germany; 11. The Lambe Institute for Translational Medicine and Curam, National University of Ireland, Galway and Saolta University Healthcare Group, Galway, Ireland
Paris Course on Revascularisation (PCR) statements are intended to represent a practical perspective from the PCR community representing a constituency of ≈60,000 active members on areas of relevant practice based on informed review of evidence and prevailing clinician interpretation. The PCR statement on paclitaxel drug-coated balloon (DCB) use in peripheral interventions was presented at EuroPCR 2019 (Paris, France) to address the ongoing controversy raised by the meta-analysis published in the Journal of the American Heart Association (JAHA). The meta-analysis prompted widespread concern by suggesting that treatment of patients with superficial femoropopliteal artery (SFA) disease using paclitaxel-coated devices (stents or DCBs) ...
Sign in to read and download the full article
Forgot your password?No account yet? Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com